Slingshot members are tracking this event:
GlycoMimetics to Release Phase 1/2 Data for GMI-1271 for Reducing Chemotherapy Resistance and Enriching T-Cells
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jun 10, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Gmi-1271, Chemotherapy Resistance, Phase 1/2 Data, T-cells